Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

[1]  R. L. Hollis,et al.  Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial , 2022, The Lancet.

[2]  B. Monk,et al.  Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC). , 2021 .

[3]  R. Drapkin,et al.  Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors. , 2021, Gynecologic oncology.

[4]  Kylie L. Gorringe,et al.  Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities , 2020, The Journal of pathology.

[5]  B. Monk,et al.  MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Huntsman,et al.  Low-grade serous ovarian cancer: State of the science. , 2020, Gynecologic oncology.

[7]  A. deFazio,et al.  PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. , 2019, Gynecologic oncology.

[8]  P. Neven,et al.  Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer , 2019, Neoplasia.

[9]  Sebastian M. Armasu,et al.  Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study , 2018, The journal of pathology. Clinical research.

[10]  E. Martinelli,et al.  Hormone receptor expression profile of low-grade serous ovarian cancers. , 2017, Gynecologic oncology.

[11]  P. Bhosale,et al.  Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. , 2017, Gynecologic oncology.

[12]  M. Birrer,et al.  Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. , 2017, Obstetrics and gynecology.

[13]  D. Bodurka,et al.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Narod,et al.  Low-grade serous ovarian cancer: A review. , 2016, Gynecologic oncology.

[15]  A. Reuss,et al.  Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. , 2016, Gynecologic oncology.

[16]  K. Wong,et al.  Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum , 2015, British Journal of Cancer.

[17]  Kylie L. Gorringe,et al.  Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes , 2015, Oncotarget.

[18]  J. Berek,et al.  International Journal of Gynecology and Obstetrics Cancer of the Ovary, Fallopian Tube, and Peritoneum , 2022 .

[19]  J. George,et al.  Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver , 2014, Clinical Cancer Research.

[20]  E. Sala,et al.  Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer , 2014, International Journal of Gynecologic Cancer.

[21]  Jaime Prat,et al.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[22]  A. Calzolari,et al.  Review of the Italian current legislation on research biobanking activities on the eve of the participation of national biobanks’ network in the legal consortium BBMRI-ERIC. , 2013, Biopreservation and biobanking.

[23]  M. Köbel,et al.  Quantification of ER/PR expression in ovarian low-grade serous carcinoma. , 2013, Gynecologic oncology.

[24]  M. Morgan,et al.  Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. , 2013, The Lancet. Oncology.

[25]  Figo Guidelines.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum☆ , 2013 .

[26]  D. Bodurka,et al.  Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. , 2012, Gynecologic oncology.

[27]  D. Bodurka,et al.  Low-grade serous primary peritoneal carcinoma. , 2010, Gynecologic oncology.

[28]  S. Mok,et al.  BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. , 2010, The American journal of pathology.

[29]  A. Sood,et al.  Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. , 2009, Gynecologic oncology.

[30]  D. Bodurka,et al.  Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. , 2008, Gynecologic oncology.

[31]  L. Cope,et al.  Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.

[32]  Michael T Deavers,et al.  Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.

[33]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[34]  M. Cummings,et al.  Increased expression of cyclin‐dependent kinase inhibitor 2 (CDKN2A) gene product P16 INK4A in ovarian cancer is associated with progression and unfavourable prognosis , 1997, International journal of cancer.